Philip Morris International reported results for the quarter ended 2026 with revenue rising to $11.19B while net earnings attributable to PMI decreased to $2.82B and diluted EPS fell to $1.8 versus the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$11.19B$10.14B10.4% | Net income²$2.82B$3.04B(7.3%) | Diluted EPS³$1.8$1.95(7.7%) |
¹ Reported as “Net revenues 1 & 2 (Note 13)”. ² Reported as “Net earnings attributable to PMI”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Net revenues rose 9.8% year-to-date to $21.3B, driven by pricing and growth in smoke-free products despite declines in combustible volumes.
- Smoke-free volumes grew 8.3% YTD (HTUs +9.4%, e-vapor +72%), while cigarettes declined 1.9%, indicating continued portfolio transition.
- Brand momentum continued with expanded availability of IQOS, ZYN and VEEV across markets; IQOS and ZYN received major FDA marketing and MRTP authorizations.
- U.S. commercialization advances included regaining full IQOS U.S. rights, an IQOS 3.0 pilot launch, and progress on ILUMA regulatory submissions.
- Company actions included lower restructuring charges, footprint optimization, and capex focused on smoke-free manufacturing expansion.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.